A $1,000 investment in Halozyme Therapeutics (HALO) made in October 2016 would be worth $11,612.33 as of October 15, 2026, representing a 1,061.23% gain. This significantly outperformed the S&P 500's 261.89% return over the same period. The biopharmaceutical company's success is driven by royalties from its ENHANZE drug delivery technology licensed to major pharma partners, though it faces headwinds from biosimilar competition on blockbuster drugs.

Keros Therapeutics announced the first patient dosing in its phase II study evaluating rinvatercept for Duchenne muscular dystrophy (DMD). The study will assess safety, tolerability, and functional improvements, with initial data expected in H1 2027. The company is also advancing rinvatercept development for ALS treatment and has a licensing agreement with Takeda Pharmaceutical for its second candidate, elritercept, with potential milestone payments exceeding $1.1 billion.

The global Enzyme Replacement Therapy (ERT) market is projected to grow from USD 12.24 billion in 2025 to USD 27.90 billion by 2035, with a CAGR of 8.59%. Growth is driven by early identification of rare lysosomal storage disorders, increased newborn screening, orphan drug incentives, and expanding healthcare access. North America leads with 38.76% market share, while Asia-Pacific shows the fastest growth at 9.43% CAGR. Imiglucerase dominates products, and Gaucher disease represents the largest therapeutic condition.

HUTCHMED announced that two Phase III studies evaluating the savolitinib and osimertinib combination for non-small cell lung cancer will be presented at ESMO Congress 2026 in Madrid. The SAFFRON global study and SANOVO China study both demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared to chemotherapy and osimertinib monotherapy, respectively. The all-oral, chemo-free combination has been selected for high-profile oral presentations including a Presidential Symposium.

The global AI in drug discovery market is projected to grow from USD 2.55 billion in 2025 to USD 31.79 billion by 2035, expanding at a 28.70% CAGR. Lead optimization and oncology applications are driving adoption, with pharmaceutical companies and biotech firms leading investment. Strategic partnerships and funding rounds, including Isomorphic Labs' $600 million raise and Takeda's $1.7 billion collaboration with Iambic Therapeutics, are accelerating market growth.

The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

Bristol Myers announced positive two-year results from the POETYK PsA-2 study showing Sotyktu (deucravacitinib) maintained durable efficacy and consistent safety through week 104. The drug generated $156 million in H1 2026 revenues, up 24% year-over-year, with potential for further expansion into lupus and Sjögren's disease indications.

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

The CAR T-cell therapy market for non-Hodgkin's lymphoma is projected to grow at a 7% CAGR from 2026 to 2036, reaching from a 2025 valuation of $3.20 billion across seven major markets. Growth is driven by broader clinical adoption, new indications, earlier-line use, and innovation in autologous and allogeneic platforms. The U.S. dominates with $1.90 billion in 2025 market value, while diffuse large B-cell lymphoma represents the largest patient population with approximately 78,000 cases across the markets.

Hummingbird Bioscience announced the appointment of Dr. James Garner as President. Garner brings over two decades of experience in drug development and commercialization from roles at Biogen, Takeda, and Sanofi, with a track record of overseeing 30+ product approvals. He previously served as CEO of Percheron Therapeutics and Kazia Therapeutics.

Zacks highlights three Rank #1 stocks with strong income potential: Ternium S.A. (TX) with a 4.5% dividend yield and 26.7% earnings estimate increase; HP Inc. (HPQ) with a 3.4% dividend yield and 8.4% earnings estimate increase; and Takeda Pharmaceutical Company Limited (TAK) with a 2.6% dividend yield and 10.7% earnings estimate increase.

The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.